Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (PBH) Stock Competitors & Peer Comparison
See (PBH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PBH | $60.91 | -0.88% | 2.9B | 16.07 | $3.79 | N/A |
| MCK | $943.25 | +0.25% | 116.4B | 27.24 | $34.63 | +0.34% |
| COR | $345.88 | -1.16% | 67.3B | 41.52 | $8.33 | +0.65% |
| CAH | $217.59 | +0.23% | 51.2B | 31.31 | $6.95 | +0.94% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $74.61 | -1.27% | 8.8B | 22.82 | $3.27 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $32.93 | +1.04% | 2.1B | 48.34 | $0.68 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| ACH | $2.42 | +1.68% | 184.2M | -1.80 | -$1.34 | N/A |
Stock Comparison
PBH vs MCK Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, MCK has a market cap of 116.4B. Regarding current trading prices, PBH is priced at $60.91, while MCK trades at $943.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas MCK's P/E ratio is 27.24. In terms of profitability, PBH's ROE is +0.10%, compared to MCK's ROE of -2.45%. Regarding short-term risk, PBH is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check MCK's competition here
PBH vs COR Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, COR has a market cap of 67.3B. Regarding current trading prices, PBH is priced at $60.91, while COR trades at $345.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas COR's P/E ratio is 41.52. In terms of profitability, PBH's ROE is +0.10%, compared to COR's ROE of +1.01%. Regarding short-term risk, PBH is less volatile compared to COR. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check COR's competition here
PBH vs CAH Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, CAH has a market cap of 51.2B. Regarding current trading prices, PBH is priced at $60.91, while CAH trades at $217.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas CAH's P/E ratio is 31.31. In terms of profitability, PBH's ROE is +0.10%, compared to CAH's ROE of -0.59%. Regarding short-term risk, PBH is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check CAH's competition here
PBH vs ABC Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, PBH is priced at $60.91, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas ABC's P/E ratio is 21.92. In terms of profitability, PBH's ROE is +0.10%, compared to ABC's ROE of +1.01%. Regarding short-term risk, PBH is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check ABC's competition here
PBH vs HSIC Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, HSIC has a market cap of 8.8B. Regarding current trading prices, PBH is priced at $60.91, while HSIC trades at $74.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas HSIC's P/E ratio is 22.82. In terms of profitability, PBH's ROE is +0.10%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, PBH is less volatile compared to HSIC. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check HSIC's competition here
PBH vs PDCO Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, PBH is priced at $60.91, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas PDCO's P/E ratio is 20.48. In terms of profitability, PBH's ROE is +0.10%, compared to PDCO's ROE of +0.06%. Regarding short-term risk, PBH is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check PDCO's competition here
PBH vs GRDN Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, GRDN has a market cap of 2.1B. Regarding current trading prices, PBH is priced at $60.91, while GRDN trades at $32.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas GRDN's P/E ratio is 48.34. In terms of profitability, PBH's ROE is +0.10%, compared to GRDN's ROE of +0.27%. Regarding short-term risk, PBH is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check GRDN's competition here
PBH vs OMI Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, PBH is priced at $60.91, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas OMI's P/E ratio is -0.47. In terms of profitability, PBH's ROE is +0.10%, compared to OMI's ROE of +7.33%. Regarding short-term risk, PBH is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check OMI's competition here
PBH vs ACH Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, ACH has a market cap of 184.2M. Regarding current trading prices, PBH is priced at $60.91, while ACH trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas ACH's P/E ratio is -1.80. In terms of profitability, PBH's ROE is +0.10%, compared to ACH's ROE of +7.33%. Regarding short-term risk, PBH is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check ACH's competition here
PBH vs GEG Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, GEG has a market cap of 58M. Regarding current trading prices, PBH is priced at $60.91, while GEG trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas GEG's P/E ratio is -4.29. In terms of profitability, PBH's ROE is +0.10%, compared to GEG's ROE of -0.21%. Regarding short-term risk, PBH is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check GEG's competition here
PBH vs HX Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, PBH is priced at $60.91, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas HX's P/E ratio is -1.84. In terms of profitability, PBH's ROE is +0.10%, compared to HX's ROE of -1.07%. Regarding short-term risk, PBH is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check HX's competition here
PBH vs RDGT Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, RDGT has a market cap of 11.7M. Regarding current trading prices, PBH is priced at $60.91, while RDGT trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas RDGT's P/E ratio is -7.65. In terms of profitability, PBH's ROE is +0.10%, compared to RDGT's ROE of +0.40%. Regarding short-term risk, PBH is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check RDGT's competition here
PBH vs SNYR Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, SNYR has a market cap of 11.6M. Regarding current trading prices, PBH is priced at $60.91, while SNYR trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas SNYR's P/E ratio is 4.64. In terms of profitability, PBH's ROE is +0.10%, compared to SNYR's ROE of -0.20%. Regarding short-term risk, PBH is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check SNYR's competition here
PBH vs WGRX Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, WGRX has a market cap of 11.6M. Regarding current trading prices, PBH is priced at $60.91, while WGRX trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas WGRX's P/E ratio is -0.13. In terms of profitability, PBH's ROE is +0.10%, compared to WGRX's ROE of -15.47%. Regarding short-term risk, PBH is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check WGRX's competition here
PBH vs ZYXI Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, PBH is priced at $60.91, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, PBH's ROE is +0.10%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, PBH is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check ZYXI's competition here
PBH vs MEHA Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, MEHA has a market cap of 1.2M. Regarding current trading prices, PBH is priced at $60.91, while MEHA trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas MEHA's P/E ratio is -3.38. In terms of profitability, PBH's ROE is +0.10%, compared to MEHA's ROE of -1.69%. Regarding short-term risk, PBH is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check MEHA's competition here
PBH vs CVET Comparison March 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.9B. In comparison, CVET has a market cap of 0. Regarding current trading prices, PBH is priced at $60.91, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 16.07, whereas CVET's P/E ratio is -69.97. In terms of profitability, PBH's ROE is +0.10%, compared to CVET's ROE of -0.06%. Regarding short-term risk, PBH is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check CVET's competition here